Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average) (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Shares Outstanding (Weighted Average) data on record, last reported at $76.2 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 21.98% to $76.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $76.2 million, a 21.98% increase, with the full-year FY2025 number at $63355.0, up 2.21% from a year prior.
  • Shares Outstanding (Weighted Average) reached $76.2 million in Q1 2026 per FULC's latest filing, up from $63355.0 in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for FULC hit a ceiling of $76.2 million in Q1 2026 and a floor of $40644.0 in Q1 2022.
  • A 5-year average of $33.8 million and a median of $61.8 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 99.87% in 2022, then surged 151474.76% in 2023.
  • Tracing FULC's Shares Outstanding (Weighted Average) over 5 years: stood at $44991.0 in 2022, then surged by 36.27% to $61310.0 in 2023, then increased by 1.1% to $61984.0 in 2024, then grew by 2.21% to $63355.0 in 2025, then skyrocketed by 120198.32% to $76.2 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for FULC at $76.2 million in Q1 2026, $63355.0 in Q4 2025, and $62.6 million in Q3 2025.